Home
OCUL
OCUL News

Latest Ocular Therapeutix Inc. (OCUL) News on September 13, 2025

Ocular Therapeutix™ to Host Investor Day on September 30, 2025

GlobeNewswire

5 days ago

Ocular Therapeutix™ to Host Investor Day on September 30, 2025

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

GlobeNewswire

3 months ago

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?

Zacks

3 months ago

Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?

Ocular Therapeutix (NASDAQ:OCUL) shareholders have earned a 33% CAGR over the last three years

Simply Wall St.

3 months ago

Ocular Therapeutix (NASDAQ:OCUL) shareholders have earned a 33% CAGR over the last three years

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

GlobeNewswire

3 months ago

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

MT Newswires

4 months ago

Sector Update: Health Care

MT Newswires

4 months ago

Ocular Shares Rise After Eye Disease Trial Nears Enrollment Completion

Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration

GlobeNewswire

4 months ago

Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

GlobeNewswire

4 months ago

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Simply Wall St.

4 months ago

Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Ocular Therapeutix First Quarter 2025 Earnings: Misses Expectations

Simply Wall St.

4 months ago

Ocular Therapeutix First Quarter 2025 Earnings: Misses Expectations

Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates

Zacks

4 months ago

Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates

MT Newswires

4 months ago

Ocular Therapeutix Q1 Net Loss Narrows, Revenue Falls

Associated Press Finance

4 months ago

Ocular Therapeutix: Q1 Earnings Snapshot

Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights

GlobeNewswire

4 months ago

Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights

Ocular Therapeutix Inc (OCUL) Q1 2025: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

4 months ago

Ocular Therapeutix Inc (OCUL) Q1 2025: Everything You Need To Know Ahead Of Earnings

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

Zacks

4 months ago

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences

GlobeNewswire

4 months ago

Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences

Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025

GlobeNewswire

5 months ago

Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

5 months ago

William Blair Initiates Ocular Therapeutix With Outperform Rating

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

GlobeNewswire

5 months ago

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

MT Newswires

6 months ago

RBC Initiates Ocular Therapeutix at Outperform, Speculative Risk With $17 Price Target

Why Ocular Therapeutix Was Bumping Higher This Week

Motley Fool

6 months ago

Why Ocular Therapeutix Was Bumping Higher This Week

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

Benzinga

6 months ago

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

MT Newswires

6 months ago

Needham Initiates Ocular Therapeutix at Buy With $15 Price Target

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix Inc (OCUL) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

GuruFocus.com

6 months ago

Ocular Therapeutix Inc (OCUL) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

Thomson Reuters StreetEvents

6 months ago

Q4 2024 Ocular Therapeutix Inc Earnings Call

Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates

Zacks

6 months ago

Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates

MT Newswires

6 months ago

Ocular Therapeutix Q4 Net Loss Narrows, Revenue Rises

Associated Press Finance

6 months ago

Ocular Therapeutix: Q4 Earnings Snapshot

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

GlobeNewswire

6 months ago

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

Ocular Therapeutix Inc (OCUL) Q4 2024: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

7 months ago

Ocular Therapeutix Inc (OCUL) Q4 2024: Everything You Need To Know Ahead Of Earnings

Amneal (AMRX) Soars 6.0%: Is Further Upside Left in the Stock?

Zacks

7 months ago

Amneal (AMRX) Soars 6.0%: Is Further Upside Left in the Stock?

Ocular Therapeutix™ to Present at Two Investor Conferences in March

GlobeNewswire

7 months ago

Ocular Therapeutix™ to Present at Two Investor Conferences in March

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

GlobeNewswire

7 months ago

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

GlobeNewswire

7 months ago

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

GlobeNewswire

8 months ago

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation

GlobeNewswire

8 months ago

Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation

Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week

Simply Wall St.

9 months ago

Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

9 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

9 months ago

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Ocular Therapeutix announces over 300 subjects randomized in SOL-1

TipRanks

9 months ago

Ocular Therapeutix announces over 300 subjects randomized in SOL-1

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

GlobeNewswire

9 months ago

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

GlobeNewswire

10 months ago

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ...

GuruFocus.com

10 months ago

Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ...

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates

Zacks

10 months ago

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates

Associated Press Finance

10 months ago

Ocular Therapeutix: Q3 Earnings Snapshot

MT Newswires

10 months ago

Ocular Therapeutix Q3 Net Loss Narrows as Revenue Increases

Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights

GlobeNewswire

10 months ago

Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights

Harrow (HROW) Reports Q3 Loss, Lags Revenue Estimates

Zacks

10 months ago

Harrow (HROW) Reports Q3 Loss, Lags Revenue Estimates

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

GlobeNewswire

10 months ago

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

What To Expect From Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings

GuruFocus.com

10 months ago

What To Expect From Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings

Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer

GlobeNewswire

10 months ago

Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

GlobeNewswire

10 months ago

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

MT Newswires

a year ago

Scotiabank Initiates Ocular Therapeutix at Sector Outperform

MT Newswires

a year ago

Ocular Therapeutix Speeds Up Timeline for Phase 3 Trial of Wet AMD Therapy; Shares Rise 7% Pre-Bell

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

GlobeNewswire

a year ago

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?

Zacks

a year ago

Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

GlobeNewswire

a year ago

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Here's What Could Help Ocular Therapeutix (OCUL) Maintain Its Recent Price Strength

Zacks

a year ago

Here's What Could Help Ocular Therapeutix (OCUL) Maintain Its Recent Price Strength

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

GlobeNewswire

a year ago

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Present at September Retina Meetings

GlobeNewswire

a year ago

Ocular Therapeutix™ to Present at September Retina Meetings

Ocular Therapeutix™ to Present at Two Investor Conferences in September

GlobeNewswire

a year ago

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Wall Street Analysts See an 85.43% Upside in Ocular Therapeutix (OCUL): Can the Stock Really Move This High?

Zacks

a year ago

Wall Street Analysts See an 85.43% Upside in Ocular Therapeutix (OCUL): Can the Stock Really Move This High?

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

With 65% ownership of the shares, Ocular Therapeutix, Inc. (NASDAQ:OCUL) is heavily dominated by institutional owners

Simply Wall St.

a year ago

With 65% ownership of the shares, Ocular Therapeutix, Inc. (NASDAQ:OCUL) is heavily dominated by institutional owners

MT Newswires

a year ago

Ocular Therapeutix Says FDA Agrees on Regulatory Path for Axpaxli in Wet AMD

MT Newswires

a year ago

Ocular Therapeutix's Shares Rise After Higher Q2 Revenue That Beat Forecast

Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates

Zacks

a year ago

Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates

Associated Press Finance

a year ago

Ocular Therapeutix: Q2 Earnings Snapshot

Ocular Therapeutix™ Reports Second Quarter 2024 Results

GlobeNewswire

a year ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD

GlobeNewswire

a year ago

Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

GlobeNewswire

a year ago

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

GlobeNewswire

a year ago

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

The one-year returns have been notable for Ocular Therapeutix (NASDAQ:OCUL) shareholders despite underlying losses increasing

Simply Wall St.

a year ago

The one-year returns have been notable for Ocular Therapeutix (NASDAQ:OCUL) shareholders despite underlying losses increasing

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

GlobeNewswire

a year ago

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

a year ago

Ocular Therapeutix Shares Rise After TD Cowen Upgrades Rating, Increases Price Target

MT Newswires

a year ago

TD Cowen Upgrades Ocular Therapeutix to Buy From Hold, Adjusts Price Target to $11 From $7

MT Newswires

a year ago

Sector Update: Health Care Stocks Decrease Late Afternoon

MT Newswires

a year ago

Ocular Therapeutix Shares Rise Following Clinical Development Progress Report

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

GlobeNewswire

a year ago

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

An Intrinsic Calculation For Ocular Therapeutix, Inc. (NASDAQ:OCUL) Suggests It's 45% Undervalued

Simply Wall St.

a year ago

An Intrinsic Calculation For Ocular Therapeutix, Inc. (NASDAQ:OCUL) Suggests It's 45% Undervalued

Ocular Therapeutix® to Host Investor Day on June 13, 2024

GlobeNewswire

a year ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

a year ago

Ocular Therapeutix Cutting 13% of Workforce

MT Newswires

a year ago

Piper Sandler Starts Ocular Therapeutix With Overweight Rating, $15 Price Target

Ocular Therapeutix Inc Reports First Quarter 2024 Earnings

GuruFocus.com

a year ago

Ocular Therapeutix Inc Reports First Quarter 2024 Earnings

Associated Press Finance

a year ago

Ocular Therapeutix: Q1 Earnings Snapshot

Ocular Therapeutix™ Reports First Quarter 2024 Results

GlobeNewswire

a year ago

Ocular Therapeutix™ Reports First Quarter 2024 Results

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

GlobeNewswire

a year ago

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

GlobeNewswire

a year ago

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

GlobeNewswire

a year ago

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

Share on Social Networks: